Fortunately in the past few years, novel adipokines have been identified such as visfatin, LCN2, nesfatin-1, RBP-4, apelin, and vaspin that may have osteoprotective/osteoanabolic effects and thus could serve as potential therapeutic targets for osteoporosis and other metabolic bone diseases. This evidence concerns the gene LCN2 and osteoporosis.